SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present new
clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12
[tavokinogene telseplasmid or "tavo"] with electroporation), its
lead program focused on oncology, at the upcoming 9th World
Congress of Melanoma – A Joint Meeting with the Society for
Melanoma Research (SMR). In addition, Chris
Twitty, Ph.D., Executive Director of Clinical Science, gave
an oral presentation at the 2nd Annual Biomarkers & Precision
Medicine USA Congress earlier this
week.
"We are excited to share updated data from our phase 2 clinical
monotherapy trial with ImmunoPulse IL-12 in patients with stage
III/IV melanoma," said Punit
Dhillon, CEO and President at OncoSec. "These data, along
with the emerging clinical data from the phase 2 combination study,
further support the rationale for our global, open-label,
registration directed phase 2b clinical trial, PISCES/KEYNOTE-695,
which we anticipate reporting initial data in mid-2018."
9th World Congress of Melanoma – A Joint Meeting with the
Society for Melanoma Research
Dr. Alain Algazi, Associate
Professor, Department of Medicine (Hematology/Oncology), at the
University of California San Francisco
(UCSF) Helen Diller Family Comprehensive Cancer Center, will give
an oral presentation contrasting monotherapy ImmunoPulse IL-12 to
its combination with pembrolizumab. The presentation includes an
assessment of clinical and immune biomarker data from the company's
recently completed monotherapy phase 2 trial. The 9th World
Congress of Melanoma – A Joint Meeting with the Society for
Melanoma Research (SMR) is to be held on October 18-22, 2017, in Brisbane, Australia.
Details of the presentation are as follows:
Abstract Title: Clinical Immune Monitoring and Biomarker
Data of pIL-12 Monotherapy Compared to pIL-12 with Pembrolizumab in
Metastatic Melanoma Supports the Rationale for Combination Therapy
(Abstract # FC05-3)
Session Title: Biology and Biomarkers
Date and Time: October 19,
2017 at 3:30 PM – 3:40 PM
Location: Brisbane Convention & Exhibition Centre
Dr. Algazi will present new clinical and immune monitoring data
from patients treated with ImmunoPulse IL-12, as a monotherapy
(n=51 patients) versus the combination of ImmunoPulse IL-12 and the
approved anti-PD-1 therapy pembrolizumab (n=22 patients) to better
understand the mechanisms associated with each immunotherapy
protocol. In the 51 patients treated with ImmunoPulse IL-12
as monotherapy, an average of 33.5% best overall response rate
(BORR) at 180 days by a modified "skin" RECIST was demonstrated, in
addition to a favorable safety profile (no life threatening or
grade 4 AE). In the combination trial of 22 patients treated to
date, a 48% BORR was observed at 24 weeks. Biomarker analyses
suggest ImmunoPulse IL-12 drives a cellular response leading to an
inflamed tumor with an increased TIL frequency whether as a
monotherapy or combined with pembrolizumab, converting "cold"
tumors to "hot".
Further details on this presentation will be provided in
upcoming Company communications. For more information about this
conference, please visit: https://worldmelanoma2017.com
2nd Annual Biomarkers & Precision Medicine USA Congress
Chris Twitty, Ph.D., Executive
Director of Clinical Science at OncoSec, gave an oral presentation
entitled: "Interrogation of the tumor microenvironment and
associated immunity in patients with melanoma" in addition to
leading a panel discussion at the 2nd Annual Biomarkers &
Precision Medicine USA Congress on
October 10, 2017 at the Hilton San
Diego Mission Valley Hotel in San Diego,
CA. For more information, please visit:
https://www.biomarkersusa-congress.com/.
About OncoSec Medical Incorporated:
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-updated-clinical-and-immune-biomarker-data-from-its-monotherapy-and-combination-therapy-studies-with-immunopulse-il-12-at-the-9th-world-congress-of-melanoma--a-joint-meeting-with-the-society-for-melanoma-resea-300535541.html
SOURCE OncoSec Medical Incorporated